๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
NCT06316427T-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2
80
Beijing, Shanghai, Chengdu
2024-03-22
Recruiting
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
NCT06752746Polycythemia Vera
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1
108
Zhengzhou, Wuhan, Nanchang, Tianjin, Hangzhou
2024-03-21
Recruiting
CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer
NCT06306612Prostate Cancer
RenJi Hospital
Not applicable
192
Shanghai
2024-03-21
Recruiting
Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery
NCT06109454Non-small Cell Lung Cancer
Liaoning Cancer Hospital & Institute
Observational
240
Shenyang
2024-03-21
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588Neoplasms, Head and Neck
GlaxoSmithKline
Phase 3
864
Chongqing, Baoding, Nanyang, Beijing, Changsha, Changzhou, Chengdu, Dongguan
2024-03-21
Active, closed
Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy Subjects
NCT06706427Bietti Crystalline Corneoretinal Dystrophy
NGGT (Suzhou) Biotechnology Co., Ltd.
Phase 1/2
12
Chongqing, Xiamen
2024-03-21
Recruiting
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
NCT06375733Large B-cell Lymphoma
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
51
Nanning, Zhengzhou
2024-03-20
Recruiting
A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
NCT06463834Esophageal Squamous Cell Carcinoma
Fujian Cancer Hospital
Phase 2
30
Fuzhou
2024-03-20
Recruiting
Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
NCT06338683Advanced Cancer, Olanzapine, Progression Free Survival
Qinghai Red Cross Hospital
Phase 3
230
Xining
2024-03-20
Active, closed
A Trial to Compare Robotic Assisted Bronchoscopy Ion's Clinical Utility for Peripheral Lung Nodule Access and Diagnosis to ENB
NCT06308120Pulmonary Nodule, Solitary, Lung Cancer
Intuitive Surgical
Not applicable
354
Shanghai, Chengdu
2024-03-20
Recruiting
Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)
NCT06221670NSCLC
Tianjin Medical University Cancer Institute and Hospital
Phase 2
51
Tianjin
2024-03-20
Recruiting
GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery
NCT06324461Myocardial Injury
The University of Hong Kong
Phase 4
372
Hong Kong
2024-03-20
Recruiting
L-arginine for Knee Osteoarthritis Patients
NCT06054633Osteoarthritis, Knee
Xiangya Hospital of Central South University
Not applicable
340
Changsha
2024-03-20
Recruiting
Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL
NCT06321289Non-hodgkin Lymphoma,B Cell
Chinese PLA General Hospital
Phase 1/2
30
Beijing
2024-03-20
Recruiting
Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study
NCT06301399Advanced Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2024-03-20
Recruiting
Safety and Efficacy of Multisensory Stimulation Virtual Reality for Stroke Patients.
NCT06275516Stroke
First Affiliated Hospital of Chongqing Medical University
Not applicable
40
Chongqing
2024-03-20
Recruiting
Establishment of Human Lung Stem Cell Proliferation System and Organoid Construction in COPD
NCT06275230Chronic Obstructive Pulmonary Disease
China-Japan Friendship Hospital
Observational
30
Beijing
2024-03-20
Recruiting
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
NCT06249438Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM), Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis (MS)
RenJi Hospital
Phase 1
30
Shanghai
2024-03-20
Recruiting
TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
NCT06301165Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
162
Guangzhou, Dongguan, Foshan, Shenzhen, Wuhan
2024-03-19
Recruiting
A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
NCT06261359Pancreatic Ductal Adenocarcinoma (PDAC)
Qilu Pharmaceutical Co., Ltd.
Phase 2
120
Beijing
2024-03-19
Active, closed
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)
NCT06304974Esophageal Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
497
Beijing
2024-03-19
By invitation
CS-101 in Patients With ฮฒ-thalassemia
NCT06328764Beta-Thalassemia
CorrectSequence Therapeutics Co., Ltd
Phase EARLY_PHASE1
10
Nanning
2024-03-19
By invitation
3T Therapy in the Treatment of MDA5-positive Dermatomyositis
NCT06438679Dermatomyositis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
133
Hangzhou
2024-03-19
Recruiting
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
NCT06767813Pancreatic Neoplasms
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
80
Zhengzhou, Nanjing, Suzhou, Shanghai, Wenzhou
2024-03-19
Recruiting
Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis
NCT06300203Seasonal Allergic Rhinitis
Beijing Tongren Hospital
Phase 2
120
Beijing
2024-03-18
Recruiting
Quantitative Superior Vena Cava Isolation in Addition to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation
NCT05908955Atrial Fibrillation
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
290
Beijing
2024-03-17
Recruiting
Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease
NCT06385106Alzheimer Disease
First Affiliated Hospital of Zhejiang University
Not applicable
30
Hangzhou
2024-03-16
Recruiting
A Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Patients With IBS-D
NCT06247046Irritable Bowel Syndrome With Diarrhea
Guangzhou Zhiyi Biotechnology Co., Ltd.
Phase 3
1,298
Wuxi, Binzhou
2024-03-16
Recruiting
A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer
NCT06312982Locally Advanced Rectal Carcinoma
Beijing Friendship Hospital
Phase 2/3
375
Beijing
2024-03-16
Recruiting
Research on Anesthesia Depth Control Strategy Based on Continuous and Non-invasive Monitoring of Exhaled Breath
NCT07272044Anesthesia
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Hangzhou
2024-03-16
Not yet open
Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke
NCT06137300Acute Ischemic Stroke
Yi Yang
Not applicable
986
Changchun
2024-03-15
Recruiting
TaVNS Improves the Symptoms of Patients With Moderate to Severe CP/CPPS
NCT06287970Chronic Prostatitis
Jiani Wu
Not applicable
68
Beijing
2024-03-15
Recruiting
Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer
NCT06467786Small Cell Lung Cancer
Tang-Du Hospital
Phase 4
24
Xi'an
2024-03-15
Recruiting
Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension
NCT06280313Unresectable Hepatocellular Carcinoma
Zhiyong Huang
Observational
60
Wuhan
2024-03-15
Recruiting
Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases
NCT06294691Acute Graft-versus-host Disease
Anhui Provincial Hospital
Phase 3
198
Hefei, Beijing, Zhengzhou, Wuhan, Shanghai, Hangzhou
2024-03-15
Recruiting
a Feasibility Study of iHD-SRT for BM
NCT06231186Brain Metastases, Adult, Stereotactic Radiotherapy
Ruijin Hospital
Not applicable
35
Shanghai
2024-03-15
Recruiting
The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
NCT06307600B Lymphoblastic Leukemia/Lymphoma
Anhui Provincial Hospital
Phase EARLY_PHASE1
9
Hefei, Wuhan
2024-03-15
Recruiting
Antifungal Agents and Infrared Thermotherapy Alone or in Combination in the Treatment of Sporotrichosis
NCT06300138Sporotrichosis
First Hospital of China Medical University
Not applicable
150
Shenyang
2024-03-15
Recruiting
Effects of Inclisiran Combined With Statins on the Morphology of Coronary Vulnerable Plaques
NCT06338293Coronary Artery Disease
Nanjing First Hospital, Nanjing Medical University
Phase 4
40
Nanjing
2024-03-15
Not yet open
A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients
NCT06255704Mantle Cell Lymphoma
Shanxi Province Cancer Hospital
Phase 2
23
Taiyuan
2024-03-15
Recruiting
Cerebellar Deep Brain Stimulation or VNS for Chronic Post-stroke Motor Rehabilitation
NCT06303960Stroke
Qilu Hospital of Shandong University
Phase EARLY_PHASE1
100
Jinan
2024-03-15
Recruiting
A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis
NCT06587685Atopic Dermatitis
Prime Gene Therapeutics Co., Ltd.
Phase 3
472
Shenyang
2024-03-15
Recruiting
The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis
NCT06244264Spinal Metastases, Blood Transfusion Complication, Lung Cancer, Surgery
Guangdong Provincial People's Hospital
Not applicable
118
Guangzhou
2024-03-15
Active, closed
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
NCT05116462Non-Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
506
Shanghai
2024-03-15
Recruiting
The Efficacy of PD-1 Monoclonal Antibody Combined With Chemotherapy in Metastatic Gastric Cancer Based on Gut Microbiota
NCT07400354Gastric Cancer, Gut Microbiota
Fudan University
Observational
300
Shanghai
2024-03-14
By invitation
The Efficacy and Safety Evaluation of 5G Tele-PCI Using R-OneTM
NCT07132255Coronary Artery Disease (CAD), Percutaneous Coronary Intervention (PCI)
Cathbot (Shanghai) Robot Co., Ltd
Not applicable
60
Jimsar, Karamay, Kashgar, Luopu, รœrรผmqi
2024-03-14
Recruiting
A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
NCT06727630Melanoma
Zhuhai Yufan Biotechnologies Co., Ltd
Phase 1/2
40
Beijing
2024-03-14
Recruiting
A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
NCT06321250Renal Cell Carcinoma Metastatic
Jemincare
Phase 1
80
Beijing
2024-03-14
Recruiting
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT06313957Relapsed B-cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma
Peking University Cancer Hospital & Institute
Phase 1
42
Beijing, Zhengzhou
2024-03-14
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310Systemic Lupus Erythematosus
AstraZeneca
Phase 3
100
Beijing, Changchun, Changsha, Dongguan, Nanjing, Shanghai, Suzhou, Wenzhou
2024-03-14
Recruiting
A Study of HLX42 in Advanced/Metastatic Solid Tumors
NCT06210815Solid Tumor and NSCLC
Shanghai Henlius Biotech
Phase 1
102
Guangdong
2024-03-14
Active, closed
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
NCT06342167Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab, Radiotherapy, Concurrent Chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
57
Beijing, Fujian, Handan, Anyang, Xinxiang, Yinchuan, Feixian, Jining
2024-03-14
Recruiting
Exploring the Difference Between Gastric Cardia Cancer and Non-cardia Gastric Cancer Based on Multiomics
NCT05812287Stomach Neoplasm
Qilu Hospital of Shandong University
Observational
120
Jinan
2024-03-14
Recruiting
A Clinical Study of CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases
NCT06318533Autoimmune Diseases
YANRU WANG
Phase EARLY_PHASE1
15
Zhenjiang
2024-03-13
Recruiting
Clinical Study of Induced Pluripotent Stem Cells Derived Motor Neuron Precursor Cell Therapy for Amyotrophic Lateral Sclerosis (ALS)
NCT06765564ALS
Shanghai East Hospital
Not applicable
3
Shanghai
2024-03-13
Active, closed
FFR Versus IVUS With Angiography-Derived FFR for Clinical Outcomes in Patients With Coronary Artery Disease
NCT06218485Coronary Artery Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,942
Beijing, Changsha, Chongqing, Ganzhou, Guangdong, Hangzhou, Huzhou, Jinan
2024-03-13
Recruiting
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
NCT06313086HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3
442
Shanghai
2024-03-13
Recruiting
Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy
NCT06037733Advanced Non-Small Cell Squamous Lung Cancer, Radiotherapy, Immunotherapy
Hubei Cancer Hospital
Not applicable
134
Wuhan
2024-03-13
Recruiting
XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
NCT06353646Pancreatic Cancer
Wu Wenming
Not applicable
28
Beijing
2024-03-12
Active, closed
Research on Precision Pharmaceutical Care for Heart Transplant Recipients
NCT06326775Heart Transplant Patients
Nanjing First Hospital, Nanjing Medical University
Observational
500
Nanjing
2024-03-12
Recruiting
A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM
NCT06590259Colorectal Cancer Liver Metastasis
Shanghai 6th People's Hospital
Phase 2
20
Shanghai
2024-03-12
Recruiting
IVUS CHIP China Registry
NCT06274645Complex Higher Risk Indicated Patients Undergoing PCI
Shanghai Zhongshan Hospital
Observational
2,020
Shanghai
2024-03-12
Recruiting
First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.
NCT06240546Advanced Solid Tumor
Luye Pharma Group Ltd.
Phase 1
102
Beijing
2024-03-12
Recruiting
Prediction and Intervention Effect of Rehabilitation Status for Severe Mental Disorder Patients Based on Multimodal Analysis and AI Agents
NCT06904079Severe Mental Disorder, Schizophrenia, Schizoaffective Disorder, Paranoid Psychosis
Shanghai Mental Health Center
Not applicable
82
Shanghai
2024-03-12
Recruiting
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414Oligometastatic Prostate Cancer (OMPC)
Novartis Pharmaceuticals
Phase 3
450
Beijing, Guangzhou, Shanghai
2024-03-12
By invitation
Vitrectomy Combined With Intravitreal Dexamethasone Implant for Idiopathic Epiretinal Membrane With Macular Oedema
NCT06232616Epiretinal Membrane
Shanghai Eye Disease Prevention and Treatment Center
Not applicable
20
Shanghai
2024-03-11
Active, closed
Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer
NCT06247956Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
153
Beijing
2024-03-11
Recruiting
Epidemiological Investigation of Helicobacter Pylori-infected Patients and the Effect of Eradication Treatment on Dyspepsia Symptoms
NCT06422052Helicobacter Pylori Infection, Dyspepsia
Shanghai Jiao Tong University School of Medicine
Observational
2,242
Chongqing, Xiamen, Wuwei, Qinzhou, Luoyang, Shangqiu, Xuchang, Wuhan
2024-03-11
Recruiting
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
NCT06339619Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
32
Guangzhou
2024-03-11
Recruiting
Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
NCT06363006Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 1
40
Beijing
2024-03-11
Recruiting
Automated Echocardiographic Detection of Coronary Artery Disease Using Artificial Intelligence Methods
NCT06314295Coronary Artery Disease
Beijing Hospital
Observational
1,500
Beijing
2024-03-11
Recruiting
Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma
NCT06215651Cadonilimab and Lenvatinib
Peking Union Medical College Hospital
Phase 2
30
Beijing
2024-03-11
Recruiting
Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients
NCT06398977Peritoneal Dialysis Complication, Renal Function Aggravated, Sodium-glucose Co-transporter-2 Inhibitors
Sichuan Academy of Medical Sciences
Not applicable
70
Chengdu
2024-03-11
Recruiting
A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS
NCT06731699AML, NHL
Chengdu FenDi Pharmaceutical Co., Ltd.
Phase 1
72
Chengdu
2024-03-11
Recruiting
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
NCT06751849Advanced NSCLC
The First Affiliated Hospital of Nanchang University
Phase 2
10
Nanchang
2024-03-11
Active, closed
Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population
NCT05902871Primary Open Angle Glaucoma, Ocular Hypertension, Normal Tension Glaucoma
BelkinVision
Not applicable
40
Hong Kong
2024-03-11
Active, closed
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer
BeiGene
Phase 1
103
Beijing, Guangzhou, Harbin, Changsha, Shenyang, Xi'an
2024-03-11
Recruiting
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
NCT06751901Advanced NSCLC
The First Affiliated Hospital of Nanchang University
Phase 2
10
Nanchang
2024-03-11
Recruiting
Metronomic Capecitabine in Stage III Gastric Cancer
NCT06313567Gastric Cancer
Fudan University
Phase 3
722
Shanghai
2024-03-10
Recruiting
Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)
NCT06261125Hepatocellular Carcinoma
Mian XI
Phase 2
60
Guangzhou
2024-03-10
Recruiting
Endoscopic Mucosal Injection Versus Ultrasound-Guided Injection of Triamcinolone to Treat Subglottic Stenosis
NCT06275269Subglottic Stenosis
China-Japan Friendship Hospital
Not applicable
40
Beijing
2024-03-10
Recruiting
A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors
NCT06292208MTD
SUNHO๏ผˆChina๏ผ‰BioPharmaceutical CO., Ltd.
Phase 1/2
48
Jinan
2024-03-09
Recruiting
Belimumab After Rituximab in Resistant Primary Juvenile SS
NCT06410833Sjogren's Syndrome, Pediatric ALL
Peking Union Medical College Hospital
Phase 4
15
Beijing
2024-03-09
By invitation
Transcutaneous Tibial Nerve Stimulation Therapy in Children With Overactive Bladder
NCT06765629Overactive Bladder (OAB)
The Children's Hospital of Zhejiang University School of Medicine
Not applicable
200
Hangzhou
2024-03-09
Recruiting
A Study of NBL-028 in Patients With Advanced Solid Tumors
NCT06223256Advanced Solid Tumor
NovaRock Biotherapeutics, Ltd
Phase 1
270
Shijiazhuang
2024-03-08
Active, closed
Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis
NCT06289452Retinoschisis, Retinal Disease, Retinal Degeneration, Eye Diseases
InnoVec Biotherapeutics Inc.
Phase EARLY_PHASE1
18
Beijing
2024-03-08
Recruiting
Standardized Procedure for Intracranial Drug-Eluting Stenting in the Treatment of Intracranial Atherosclerotic Stenosis
NCT06857058Intracranial Atherosclerotic Stenosis
Sino Medical Sciences Technology Inc.
Not applicable
300
Zhengzhou
2024-03-08
Recruiting
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
NCT06354530Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma
Army Medical Center of PLA
Phase 2/3
266
Chongqing
2024-03-08
Recruiting
XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)
NCT06055179Xiao Chai Hu Tang, Irinotecan-induced Diarrhea
Guangzhou University of Traditional Chinese Medicine
Not applicable
98
Guangzhou
2024-03-08
Active, closed
Effects of the Combined Intervention of Exercise, Fruit, and Vitamin Supplementation on Frailty in Older Adults
NCT06225271Frailty
Nanjing Medical University
Not applicable
934
Suzhou
2024-03-08
Recruiting
Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT06118788Leukemia, Myeloid, Acute
Guangzhou Bio-gene Technology Co., Ltd
Phase 1/2
24
Guangzhou, Hangzhou
2024-03-07
Recruiting
Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
NCT06277050Nasopharyngeal Carcinoma, High-Risk Cancer, Maintenance Therapy
Jiangxi Provincial Cancer Hospital
Phase 3
264
Ganzhou, Guangzhou, Nanchang
2024-03-07
Recruiting
A Study for HSK39775 in Participants With Solid Tumors
NCT06314373Advanced Solid Tumors
Xizang Haisco Pharmaceutical Co., Ltd
Phase 1/2
243
Shanghai
2024-03-07
Recruiting
Mechanism of Gamma Oscillation Synchronization in the Prefrontal-hippocampal Circuit for Memory Dysfunction in Patients With White Matter Lesions of Cerebral Small Vessel Disease
NCT07042633Vascular Cognitive Impairment, White Matter Lesions, Gamma Oscillation
Xuanwu Hospital, Beijing
Observational
150
Beijing
2024-03-07
Recruiting
An Exploratory Study by Fast CAR T Cells
NCT06327997Solid Tumor
Shanghai Cell Therapy Group Co.,Ltd
Phase EARLY_PHASE1
20
Shanghai
2024-03-07
Recruiting
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
NCT05745350Small Cell Lung Cancer Extensive Stage
Xiaorong Dong
Phase 2
45
Wuhan
2024-03-07
Recruiting
Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
NCT06314906Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting
Feixue Song
Phase 3
370
Lanzhou
2024-03-07
Recruiting
Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe
NCT06203119Cancer
Peking University Cancer Hospital & Institute
Phase 1
20
Beijing
2024-03-06
Recruiting
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
NCT06206174Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult
Shenzhen TargetRx Co., Ltd.
Phase 1/2
30
Tianjin
2024-03-06
Recruiting
Variation in the Impact of Coffee on the Metabolic Rate
NCT06432504Healthy
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Not applicable
100
Shenzhen
2024-03-06
Rows per page Showing 13301–13400 of 19052
Previous 132 133 134 135 136 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china?page=134

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.